Athira Pharma Files 8-K Report

Ticker: LONA · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1620463

Athira Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyAthira Pharma, INC. (LONA)
Form Type8-K
Filed DateSep 3, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $75.1 million
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Athira Pharma filed an 8-K, likely containing updates for investors.

AI Summary

On September 3, 2024, Athira Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates Athira Pharma is providing updates to the SEC, which could contain material information for investors regarding the company's status or upcoming events.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification without specific material disclosures that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Athira Pharma, Inc.?

The filing is primarily for Regulation FD disclosures, other events, and financial statements and exhibits, as indicated by the Item Information.

When was this 8-K report filed?

The report was filed on September 3, 2024.

What is Athira Pharma, Inc.'s principal executive office address?

The address is 18706 North Creek Parkway, Suite 104, Bothell, WA 98011.

What is Athira Pharma's IRS Employer Identification Number?

Athira Pharma's IRS Employer Identification Number is 45-3368487.

What is the Commission File Number for Athira Pharma?

The Commission File Number for Athira Pharma is 001-39503.

Filing Stats: 950 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2024-09-03 16:01:11

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On September 3, 2024, Athira Pharma, Inc. (the "Company") issued a press release announcing the topline results from the Company's Phase 2/3 LIFT-AD clinical trial. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. I tem 7.01 Regulation FD Disclosure. The Company will host a live webcast to discuss the LIFT-AD topline results at 4:30 PM Eastern time today, September 3, 2024. To access the live webcast, please visit the "Events and Presentations" page within the Investors section of the Athira website https://investors.athira.com/news-and-events/events-and-presentations-investor . The call can also be accessed by phone at 800-715-9871, conference ID: 4911242. As part of the webcast, the Company will present certain slides relating to the LIFT-AD topline results, which slides are attached as Exhibit 99.2 hereto. On September 3, 2024, the Company announced certain information relating to the Company's financial condition as of August 31, 2024, including its preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and investments, of approximately $75.1 million. The preliminary and unaudited estimate of cash resources is based on management's initial analysis of operations as of August 31, 2024, and is subject to further internal review. The information in Item 7.01 of this Current Report on Form 8-K, including the slides to be used during the webcast and attached as Exhibit 99.2 hereto, are being furnished and not filed pursuant to Item 7.01 of Form 8-K. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are identified by such words as "believe," "expect," "anticipate" and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company's plans, projections, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the Company's preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and investments. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These statements, like all statements in this report, speak only as of their date. The preliminary expectations regarding cash, cash equivalents, and investments as of August 31, 2024 are the responsibility of management, are subject to management's review and actual results could differ from management's expectations. No assurance is given by the Company's independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of August 31, 2024, based on the foregoing estimates.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Athira Pharma, Inc. press release dated September 3, 2024. 99.2 Athira Pharma, Inc. presentation slides. 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Athira Pharma, Inc. Date: September 3, 2024 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing